STRENGTH - The Roxolid® MATERIAL

Roxolid material is the first Titanium-Zirconium (TiZr) alloy material designed specifically for dental implants. It offers more confidence when placing implants, the flexibility of having more treatment options and can help to increase patient acceptance of implant treatment.

Higher tensile1 strength when compared to Straumann® Titanium implants

1Norm ASTM F67 (states min. tensile strength of annealed titanium).

2Gottlow J, et al. Evaluation of a new titanium-zirconium dental implant: a biomechanical and histological comparative study in the mini pig. Clin Imp Dent Relat Res. 2012. Aug;14(4);538-545.

SCIENTIFIC EVIDENCE

In a pre-clinical study in the mini-pig, Roxolid® outperformed Straumann Titanium SLActive® in 2 out of 3 osseointegration parameters1

Download Whitepaper

Parameter Roxolid Titanium P-Value
Bone Area Within the Chamber 45.5 ± 13.2% 40.2.2 ± 15.2% 0.023
Removal Torque (Ncm) 230.9 ± 22.4% 204.7 ± 24.0% 0.013
Bone to Implant Contact (BIC) 70.2 ± 17.3%
72.3 ± 20.5% 0.96 (NS)

1Gottlow J, et al. Evaluation of a new titanium-zirconium dental implant: a biomechanical and histological comparative study in the mini pig. Clin Imp Dent Relat Res. 2012. Aug;14(4);538-545.

The First Clinical Study of Roxolid® over a 2-year Time Period1

Download Whitepaper

  • Human study to show performance and tolerability
  • Minimal crestal bone change observed 2 years after implant loading
  • Conclusions
    • High implant stability
    • Good osseointegration properties
  Baseline 1 Year 2 Years
Mean 0 -0.16 -0.33
SD 0 ±0.42 ±0.54

Table shows: The mean bone level changes from the baseline (in mm)

1Barter S, Stone P, Brägger U. A pilot study to evaluate the success and survival rate of Titanium-Zirconium implants in partially edentulous patients: Results after 24 months of follow-up. Clin. Oral Implants Res. 23, 2012; 873-881.

Roxolid® – 2-Year Results from a Multicenter Study1

Download Whitepaper

  • Double-blind, split-mouth multicenter study to show that Roxolid performed at least as well as titanium grade 4 implants
  • 8 sites in 5 countries
  • 2-year follow-up survival rates of 98.8% (Roxolid) and 97.5% (titanium)
  • No significant difference in peri-implant bone level change after implant placement between the two groups
  • Conclusions supported the hypothesis
Survival Rate (%) Roxolid® Titanium
12 Months After Surgery 98.9% (based on 88 patients)
97.7% (based on 88 patients)
24 Months After Surgery 98.8% (based on 82 patients)
97.5% (based on 81 patients)

Table shows: Implant survival rate 12 and 24 months after surgery

1Müller F. Academy of Osseointegration 26th Annual Meeting, Washington DC, March 2011; oral presentation.